The themes BlossomHill Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from BlossomHill Therapeutics, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$16.10+12.7%Nov 11 close
The latest quarter (ended September 30, 2026) is from BlossomHill Therapeutics’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once BlossomHill Therapeutics files it.
Not rated
The band under the price shows the grade on each date, built only from filings that were public by then.
There is no grade history to chart for BlossomHill Therapeutics, Inc. yet. The quarterly grade is rebuilt from only the filings that were public at the time, and this company has not yet reported enough of them to score a single quarter.